Terminated PHASE2 INTERVENTIONAL 1-arm NCT01556347

Multi-Drug Desensitization Protocol for Heart Transplant Candidates

Sponsor: Providence Health & Services

Interventions Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis

Updated 10 times since 2017 Last updated: Jun 11, 2018 Started: Jul 31, 2012 Primary completion: May 31, 2016 Completion: May 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of efficacy

Other terminated trials from Providence Health & Services

See all terminations from Providence Health & Services

A PHASE2 clinical study on Heart Transplantation, this trial is terminated or withdrawn. The trial is conducted by Providence Health & Services and has accumulated 10 data snapshots since 2012. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2
Dec 2021 — Dec 2022 [monthly]

Terminated PHASE2

▶ Show 5 earlier versions

Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Jul 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2018 — Jul 2018 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Providence Health & Services

Data source: Providence Health & Services

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Spokane, United States